B. Metzler seel. Sohn & Co. Holding AG Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) in the third quarter, HoldingsChannel reports. The fund bought 9,280 shares of the company’s stock, valued at approximately $3,098,000.

Several other hedge funds have also modified their holdings of MEDP. O Shaughnessy Asset Management LLC acquired a new stake in Medpace in the first quarter valued at approximately $307,000. Natixis purchased a new position in shares of Medpace in the first quarter valued at $727,000. MQS Management LLC purchased a new position in shares of Medpace in the first quarter valued at $318,000. EntryPoint Capital LLC acquired a new stake in Medpace during the 1st quarter valued at $54,000. Finally, CreativeOne Wealth LLC purchased a new stake in Medpace during the 1st quarter worth $1,304,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Redburn Atlantic began coverage on Medpace in a research note on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. TD Cowen dropped their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, UBS Group downgraded shares of Medpace from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $380.00.

Read Our Latest Stock Report on Medpace

Medpace Price Performance

MEDP stock opened at $326.09 on Thursday. The firm has a fifty day moving average price of $340.65 and a two-hundred day moving average price of $374.33. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The firm has a market cap of $10.13 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 1.72 and a beta of 1.37.

Medpace (NASDAQ:MEDPGet Free Report) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.22 earnings per share. As a group, analysts expect that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.